Millions of adults know their LDL cholesterol number, but new research suggests another measurement may provide an even better understanding of heart disease risk for some people.
Researchers are drawing increased attention to apolipoprotein B (apoB), a blood test that measures the number of cholesterol-carrying particles circulating through the bloodstream. According to the study, apoB may offer a more accurate assessment of cardiovascular risk than LDL cholesterol alone because it focuses on the particles that can contribute to plaque buildup inside the arteries.
For decades, LDL cholesterol has been one of the most common ways doctors estimate heart disease risk. New research suggests another measurement—known as apolipoprotein B, or apoB—may provide an even clearer picture for some patients.
Traditional LDL cholesterol tests measure how much cholesterol is being carried through the bloodstream. ApoB testing takes a different approach by measuring the number of cholesterol-carrying particles themselves. Researchers say that particle count may provide a more accurate picture of heart disease risk because each particle has the potential to contribute to plaque buildup inside the arteries.
The findings are particularly noteworthy because some people with normal LDL cholesterol levels still experience heart attacks or develop cardiovascular disease. Researchers believe that in certain cases, an individual may have a normal amount of cholesterol overall while still carrying a higher-than-expected number of cholesterol particles. ApoB testing can help identify that additional risk.
The research is expected to contribute to the ongoing discussion about how cardiovascular disease is assessed and prevented. While LDL cholesterol remains an important part of routine screening, many experts believe apoB testing may become an increasingly valuable tool for evaluating overall heart health, particularly for patients with additional risk factors such as diabetes, obesity, or metabolic syndrome.
The findings don’t mean LDL cholesterol testing should be ignored or that everyone needs additional testing. Instead, the research suggests apoB may become an increasingly valuable tool for assessing cardiovascular risk in some patients. Anyone with questions about cholesterol testing should discuss the options with their healthcare provider, who can recommend the most appropriate approach based on individual health and risk factors.
As researchers continue searching for better ways to predict and prevent heart disease, studies like this may help doctors identify higher-risk patients earlier, allowing for more personalized treatment and prevention strategies.
The Readovia Lens
Medical research continues to move toward more personalized healthcare. Rather than relying on a single measurement, researchers are increasingly combining multiple indicators to better understand an individual’s overall health and risk. As science advances, the future of preventive care may depend on creating a more complete picture rather than relying on any one number alone.
